Table 3. Ongoing clinical trials with PAN-PI3K inhibitors in head and neck cancer patients.
| Compound | Combination | Phase | State | NCT number |
|---|---|---|---|---|
| Buparlisib | / | 2 | Unknown | NCT01527877 |
| / | 2 | Recruiting | NCT01737450 | |
| Cisplatin + IMRT | 1b | Recruiting | NCT02113878 | |
| Paclitaxel | 2 | Not yet recruiting | NCT01852292 | |
| Cetuximab | 2 | Not yet recruiting | NCT01816984 | |
| Cisplatin/ Carboplatin | 1b | Not yet recruiting | NCT02439489 | |
| Copanlisib | Cetuximab | 1+2 | Recruiting | NCT02822482 |
IMRT: Intensity-modulated radiation therapy, NCT: Number clinicaltrials.gov identifier.